NASDAQ:ME 23andMe (ME) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free ME Stock Alerts $0.50 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.49▼$0.5250-Day Range$0.36▼$0.6652-Week Range$0.35▼$2.21Volume2.20 million shsAverage Volume6.93 million shsMarket Capitalization$242.57 millionP/E RatioN/ADividend YieldN/APrice Target$0.47 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get 23andMe alerts: Email Address 23andMe MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside6.4% Downside$0.47 Price TargetShort InterestHealthy10.48% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.22Based on 2 Articles This WeekInsider TradingSelling Shares$78,638 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.53 out of 5 starsMedical Sector5083rd out of 5,430 stocksPharmaceutical Preparations Industry2383rd out of 2,526 stocks 1.0 Analyst's Opinion Consensus Rating23andMe has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst Coverage23andMe has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted10.48% of the float of 23andMe has been sold short.Short Interest Ratio / Days to Cover23andMe has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 23andMe has recently decreased by 10.58%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield23andMe does not currently pay a dividend.Dividend Growth23andMe does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ME. Previous Next 1.5 News and Social Media Coverage News Sentiment23andMe has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for 23andMe this week, compared to 7 articles on an average week.Search InterestOnly 17 people have searched for ME on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat Follows10 people have added 23andMe to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 23andMe insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $78,638.00 in company stock.Percentage Held by Insiders27.55% of the stock of 23andMe is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.10% of the stock of 23andMe is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of 23andMe is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 23andMe is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio23andMe has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About 23andMe Stock (NASDAQ:ME)23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Read More ME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ME Stock News HeadlinesApril 20, 2024 | insidertrades.com23andMe Holding Co. (NASDAQ:ME) Insider Sells $18,117.56 in StockMay 1, 2024 | ca.style.yahoo.comAmazon deal: These 23andMe DNA kits are up to $100 off right now — 'results are truly amazing'May 4, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 30, 2024 | businesswire.comPotter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach CaseApril 24, 2024 | globenewswire.com23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2024 | fool.comThis Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be NextApril 19, 2024 | finance.yahoo.com23andMe CEO Anne Wojcicki Says She’s Weighing Buyout BidApril 19, 2024 | msn.comOnce Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's FutureMay 4, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 18, 2024 | reuters.comColumn: Law firm Edelson pitches radical idea for picking lead in 23andMe case. Ask class members.April 18, 2024 | bizjournals.com23andMe going privateApril 18, 2024 | msn.com23andMe's business is basically worthless. Its CEO now wants to buy it.April 18, 2024 | proactiveinvestors.com23andMe CEO reveals take-private planApril 18, 2024 | investorplace.comME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private DealApril 18, 2024 | investopedia.com23andMe CEO Wojcicki Plans To Take DNA-Testing Firm PrivateApril 18, 2024 | cnbc.com23andMe CEO Anne Wojcicki considers taking company privateApril 18, 2024 | seekingalpha.comWall Street Breakfast Podcast: TikTok Divestment Bill On Potential Fast TrackApril 18, 2024 | msn.com23andMe Holding (ME) Price Target Decreased by 13.33% to 1.26April 18, 2024 | msn.com23andMe CEO Anne Wojcicki eyes taking DNA-testing company privateApril 18, 2024 | finance.yahoo.com23andMe announces CEO’s intention to pursue a potential take-privateApril 18, 2024 | globenewswire.com23andMe announces CEO's intention to pursue a potential take-privateApril 18, 2024 | 247wallst.com23andMe May Disappear as Public StockApril 18, 2024 | msn.com23andMe CEO Anne Wojcicki Plans to Take Company PrivateApril 17, 2024 | reuters.com23andMe CEO Wojcicki considering taking firm private, filing showsApril 17, 2024 | finance.yahoo.comCan 23andMe Holding (NASDAQ:ME) Afford To Invest In Growth?April 15, 2024 | bizjournals.com23andMe shrinks its South San Francisco headquarters footprintApril 15, 2024 | msn.comKim Kardashian, Elon Musk: Breakthrough Prize Red Carpet PhotosSee More Headlines Receive ME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today5/03/2024Next Earnings (Estimated)5/23/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ME CUSIPN/A CIK1804591 Webvgacquisition.com Phone650-938-6300FaxN/AEmployees769Year FoundedN/APrice Target and Rating Average Stock Price Target$0.47 High Stock Price Target$0.47 Low Stock Price Target$0.47 Potential Upside/Downside-6.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-311,660,000.00 Net Margins-210.48% Pretax Margin-210.71% Return on Equity-52.99% Return on Assets-39.32% Debt Debt-to-Equity RatioN/A Current Ratio2.15 Quick Ratio2.04 Sales & Book Value Annual Sales$299.49 million Price / Sales0.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book0.32Miscellaneous Outstanding Shares482,920,000Free Float349,873,000Market Cap$242.57 million OptionableNot Optionable Beta1.24 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMs. Anne WojcickiCo-Founder, CEO, President & Chair of the BoardMr. Joseph Selsavage (Age 61)Interim CFO & Accounting Officer Comp: $574.56kKey CompetitorsPuma BiotechnologyNASDAQ:PBYIAC ImmuneNASDAQ:ACIUAquestive TherapeuticsNASDAQ:AQSTImmutepNASDAQ:IMMP2seventy bioNASDAQ:TSVTView All CompetitorsInsiders & InstitutionsWittenberg Investment Management Inc.Bought 893,552 shares on 5/3/2024Ownership: 0.474%China Universal Asset Management Co. Ltd.Bought 24,604 shares on 4/29/2024Ownership: 0.013%Kathy L HibbsSold 38,548 sharesTotal: $18,117.56 ($0.47/share)Mirador Capital Partners LPBought 34,321 shares on 4/18/2024Ownership: 0.071%Kathy L HibbsSold 38,548 sharesTotal: $19,274.00 ($0.50/share)View All Insider TransactionsView All Institutional Transactions ME Stock Analysis - Frequently Asked Questions Should I buy or sell 23andMe stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ME, but not buy additional shares or sell existing shares. View ME analyst ratings or view top-rated stocks. What is 23andMe's stock price target for 2024? 1 brokerages have issued 12 month price targets for 23andMe's shares. Their ME share price targets range from $0.47 to $0.47. On average, they predict the company's stock price to reach $0.47 in the next twelve months. This suggests that the stock has a possible downside of 6.4%. View analysts price targets for ME or view top-rated stocks among Wall Street analysts. How have ME shares performed in 2024? 23andMe's stock was trading at $0.9135 on January 1st, 2024. Since then, ME shares have decreased by 45.0% and is now trading at $0.5023. View the best growth stocks for 2024 here. When is 23andMe's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our ME earnings forecast. How were 23andMe's earnings last quarter? 23andMe Holding Co. (NASDAQ:ME) announced its quarterly earnings data on Wednesday, February, 7th. The company reported ($0.17) earnings per share (EPS) for the quarter. The company earned $44.75 million during the quarter, compared to analysts' expectations of $56.30 million. 23andMe had a negative trailing twelve-month return on equity of 52.99% and a negative net margin of 210.48%. What ETF holds 23andMe's stock? Global X Telemedicine & Digital Health ETF holds 309,551 shares of ME stock, representing 0.24% of its portfolio. What guidance has 23andMe issued on next quarter's earnings? 23andMe issued an update on its FY 2024 earnings guidance on Wednesday, February, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $215.0 million-$220.0 million, compared to the consensus revenue estimate of $245.5 million. Who are 23andMe's major shareholders? 23andMe's stock is owned by many different retail and institutional investors. Top institutional investors include Wittenberg Investment Management Inc. (0.47%), Mirador Capital Partners LP (0.07%) and China Universal Asset Management Co. Ltd. (0.01%). Insiders that own company stock include Kathy L Hibbs, Kenneth J Hillan and William G Richards. View institutional ownership trends. How do I buy shares of 23andMe? Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ME) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe Gold Grab of the CenturyColonial Metals4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.